ABCC9
ENSG00000069431
Target class
Transporter
Chromosome
12
Approved drugs
2
Clinical candidates (approved and in development)
4
- Approved drugs
- 2
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- No
- Target name
- ABCC9
- Gene name
- ATP binding cassette subfamily C member 9
- Gene symbol
- ABCC9
- Protein name
- ATP-binding cassette sub-family C member 9 (Sulfonylurea receptor 2)
- SUR2
- CMD1O
- Gene biotype
- Protein coding
- Gene family
- ATP binding cassette subfamily C
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 49
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 21.82
- Tissue specificity (Gini)
- 0.492
- Tissue specificity (tau)
- 0.74
- KEGG gene identifiers
- hsa:10060
- Protein interaction confidence
- 0.797545
- Protein interaction partners
- 11
- R-HSA-1296025
- R-HSA-382556
- R-HSA-5578775
- R-HSA-5678420
- End position
- 21942543
- Start position
- 21797389
- Chromosome
- 12
- Strand
- Reverse
- Membrane
- Multi-pass membrane protein .
- Nucleoplasm
- Plasma membrane
- Tissue specificity (tau)
- 0.740103
- Expression inequality (Gini)
- 0.491597
Expression in transcripts per million
- Uterus
- 21.82
- Fallopian Tube
- 18.29
- Adipose - Subcutaneous
- 16.97
- Cells - Cultured fibroblasts
- 16.55
- Muscle - Skeletal
- 16.17
Expression in transcripts per million
- Uterus21.82
- Fallopian Tube18.29
- Adipose - Subcutaneous16.97
- Cells - Cultured fibroblasts16.55
- Muscle - Skeletal16.17
- Esophagus - Gastroesophageal Junction15.03
- Esophagus - Muscularis13.08
- Adipose - Visceral (Omentum)12.83
- Artery - Tibial12.81
- Cervix - Endocervix11.63
- Cervix - Ectocervix11.36
- Breast - Mammary Tissue10.1
- Liver8.69
- Thyroid8.48
- Heart - Left Ventricle8.41
- Colon - Sigmoid8.26
- Nerve - Tibial7.77
- Ovary7.76
- Artery - Coronary7.71
- Heart - Atrial Appendage7.49
- Lung6.56
- Artery - Aorta5.99
- Bladder5.67
- Vagina5.21
- Prostate5.13
And 29 more, listed on the interactive page.
- GO:0033198
- GO:0051607
- GO:0055085
- GO:0061337
- GO:0071805
- GO:0005886
- GO:0008282
- GO:0005267
- GO:0042626
- GO:0044325
abnormal pulse
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: abnormal pulse
- pancreas
- renal
- cardiovascular
PubMed 28216264increased/decreased blood glucose
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased/decreased blood glucose
- pancreas
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood pressure
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood glucose
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased blood glucose
- pancreas
- renal
- cardiovascular
PubMed 28216264cardiac lesions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac lesions
- pancreas
- renal
- cardiovascular
PubMed 28216264increased heart rate
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased heart rate
- pancreas
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: cardiac arrhythmia
- pancreas
- renal
- cardiovascular
PubMed 28216264atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased blood insulin
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased blood insulin
- pancreas
- renal
- cardiovascular
PubMed 28216264decreased convulsions
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased convulsions
- pancreas
- renal
- cardiovascular
PubMed 28216264increased blood insulin
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased blood insulin
- pancreas
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- pancreas
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (503)
- 24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
- A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
- A Bioequivalence Study of Glibenclamide From Glibesyn 5 mg Tablets (Medochemie LTD Cyprus) and Daonil 5 mg Tablets (Sanofi-Aventis Cyprus Ltd. )
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
- A Comparison Between Two Oral Hypoglycemics - Metformin and Glybenclamide for the Treatment of Gestational Diabetes Mellitus
- A Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
- A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)
- A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of LY3871801 in Healthy Participants
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
- A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
- A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
- A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS
Drugs (11)
- Glibornuride
- Gliclazide
- Glimepiride
- Glyburide
- Minoxidil Sulfonylurea receptor 2, Kir6.2 opener
- Naminidil Sulfonylurea receptors; K-ATP channels opener
- Nateglinide
- Pinacidil Sulfonylurea receptor 2, Kir6.2 opener
- Pinacidil anhydrous Sulfonylurea receptor 2, Kir6.2 opener
- Repaglinide
- Sarakalim Sulfonylurea receptors; K-ATP channels opener